Chapter 25: Nucleotide Biosynthesis

Chapter 25: Nucleotide Biosynthesis

• The authors describe the synthesis of the purine and pyrimidine nucleotides in this chapter.
• In the opening paragraph of the chapter, there are a number of important roles that these compounds serve.
• An outline for the synthesis of nucleotides through de novo and salvage pathways is reviewed in the introduction to the chapter.

• The chapter begins with the synthesis of pyrimidine nucleotides.
• After attachment to a ribose sugar, the pyrim idine ring is synthesised de novo from bicarbonate, aspartate, and ammonia.
• The authors go through the synthesis step-by-step, paying particular attention to the synthesis of pyrimidine by theCPS.

• The next step in the synthesis is catalyzed by aspartate transcarbamoylase.
• This reaction is the first step in prokaryotic pyrimidine synthesis.
• A condensation and an oxidation reaction complete the formation of orotate, which is then coupled to a phosphoribose by reaction with 5-ribosyl-1-pyrophosphate.

• UMP can be phosphorylated by mono- and diphosphate kinases if orotidylate is decarboxylated.
• The synthesis of the pyrimidine ribonucleotides is completed by amination of UTP.

• The authors are going to synthesise the purine nucleotides.
• The synthesis of purine nucleotides builds upon the ribose ring.

• The ribose sugar is donated by the activated form of ribose 5-phosphate.
• The two purine nucleotides are related.
• The synthesis of this initial purine product is discussed by the authors.
• There are two reactions that allow cells to save free purines.
• In the chapter, feedback inhibition is discussed.

• Two reactions that are required to form the precursors of DNA are described in detail.
• The authors show the mechanisms and cofactors of the enzymes and explain how some drugs and antibiotics work.
• The synthesis of the cofactors of NAD+, NADP+, FAD, and CoA is described briefly.
• The chapter ends with an explanation of how the purines are catabolized and some of the pathological conditions that arise from defects in the catabolic pathway of the purines.

• You should be able to complete the objectives once you have mastered this chapter.

• Draw the structure of a pyrimidine ring and identify the precursors that make up the carbon and nitrogen atoms.
• The ring atoms are numbered.

• Pick out the carbon and nitrogen atoms of the ring by drawing it.
• The ring atoms are numbered.

• List the steps that are required.

• The reactions have cofac tors and intermediates.

• Account for the source of the group and describe the oxidation state of the transferred carbon atom that occurs during the reaction.

• The biosynthesis of the purine and pyrimidine nucleotides is regulated.

• There is a purine base.

• Pick the compounds that are precursors of 2'-deoxythymidine 5-triphosphate (dTTP) in mammals and place them in their correct biosynthetic order.

• Both methotrexate and trimethoprim can be used to treat dihyrofolate reductase.

• The source of derivatives that are activated intermediates in many biosyntheses is the source of the nucleotides, as well as the universal currency of energy in biological systems, and GTP.

• Nucleotides have one or more phosphate substituents on their ribose or deoxyribose moieties.

• Orotate condenses with PRPP in a reaction catalyzed by orotate phosphoribosyl trans ferase to form the nucleotide orotidylate.
• The reaction occurs during the synthesis of pyrimidine.

• The dNMPs and NMPs are phosphorylate by different specific nucleoside monophosphate kinases.
• The dNDPs and NDPs are converted to dNTPs and NTPs by a single enzyme.
• Adenylate kinase converts the ubiquitous adenylate nucleotides.

• There is amination of UTP.
• The carbonyl oxygen at C-4 of UTP is replaced with an enol phosphate ester intermediate.

• A, c, d, e. A carbonyl oxygen is converted into a phosphoryl ester or a substituted phosphoryl ester through a reaction with a high-energyphosphate.
• The side-chain amide group of glutamine or the a-amino group of aspartate can be used to displaced thephosphate group.
• The adduct can be converted into a group.

• 14.
• The activated form of ribose 5-phosphate reacts with the purine base to form the nucleotide and release PPi.
• The energy is provided by the reaction with R-5-P.

• DNDPs are converted by ribonucleotide re ductase in mammals.
• dUDP is converted to dUTP by the nucleoside diphosphate kinase.
• A specific pyrophosphatase hydrolyzes dUTP to dUMP, which is then converted to dTP.
• The dTP is converted to dTTP.
• You might have expected the dUDP product of the ribonucleotide reductase reaction to be converted to dUMP.
• Cells contain a dUTP pyrophosphatase that is used to prevent dUTP from serving as a DNA precursor, and it is also used in the dTTP biosynthetic pathway.

• A suicide inhibitor is a substance that is capable of reacting with and inactivating an enzyme.
• The pyrimidine biosynthesis process involves the conversion of fluorouracil into a derivative that becomes covalently attached to the enzyme.

• Since trimethoprim doesn't bind to the dihydrofolate reductase in the same way that methotrexate does, it causes less harm to humans.

• There are three compounds involved in the regulation.

• If the supply of the essential amino acid tryp tophan is insufficient, niacin becomes a requirement.

• Each of these compounds has a purine base.

• Urate levels in humans can be close to the limit, which can lead to gout when salts of urate are present.
• urate is a highly effective scavenger of reactive oxygen species, so high concentrations of urate are beneficial.
• Aging and cancer can be caused by ROS.
• Ascorbate is more effective than Urate.

• The mammals don't grow or divide because they don't have adenosine deaminase.
• The level of dATP in these cells is 100 times higher than in normal lymphocytes, and the synthesis of DNA in the cells is impaired.

• The first step is catalyzed by a specific nucleoside kinase.

• Suggestions on how the administration of methotrexate could affect the action of F-dUMP.

• A deficiency of any of the urea cycle enzymes can cause elevated levels of ammonia in the blood.

• There are two types of disorders that can be distinguished by the presence of orotic acid in the urine.

• The b-aminoisobutyrate can be converted to CoA and then degraded in the citric acid cycle, as shown in the figure below.

• You want to prepare 14C-labeled purines by growingbacteria in a medium with a labeled precursor.
• The only way to get the same activity per carbon atom is to use the same amino acids.

• The purine salvage pathway can be used to convert 6-Mercaptopurine (6-MP) to tIMP.
• Because of the synergistic effect they have on each other, 6-MP and MTX have been used together for many years in the treatment of childhood leukemia.

• Hydroxyurea has been shown to interfere with DNA synthesis and is used as an anti-cancer agent.

• nucleic acid biosynthesis is interfered with by methotrexate.

• The constant for each reaction is close to 1.

• When deoxyadenosine or deoxyguanosine is added to the medium, it is often observed that the inclusion of thymine into DNA is enhanced.

• The ribose 1-phosphate to ribose 5-phosphate isomerization isomerized by the nucleoside phosphorylase and phosphoribomutase.

• nicotinamide is found in many multivitamin preparations.
• nicotinamide is converted directly to NAD+ in most mammals.

• Hypoxanthine-guanine phosphoribosyl transferase (HGPRT) uses 5'-phosphoribosylpyrophosphate to convert hypox anthine to IMP and guanine.
• Excess formation of uric acid and gout can be caused by a deficiency of this enzyme.

• It is catalyzed by aspartate transcarbamoylase.

• The synthesis can be done from both dUMP and dCMP.
• The route from dCMP begins with the formation of dCDP from CDP, followed by dephosphorylation to dCMP, and the deamination of dCMP to form dUMP, catalyzed by dCMP deam.

• 2O + H+ dUMP + NH3 dCMP deaminase is anosteric and is stimulated by dCTP.
• Refer to these effects as the regulation of ribonucleotide reductase by deoxynucleoside triphosphates.

• The clustering of two or more active sites in a single polypeptide chain ensures that their synthesis is coordinated and helps assure that they will assemble into a coherent complexample.
• A complex formed by noncovalent interactions is likely to be more stable than a complex formed by covalently linked active sites.

• Through the action of a specific monophosphate kinase, the conversion ofAMP toADP is accomplished.
• The reduction of ADP to dADP is done by ribonucleotide reductase.

• The deoxyribonucleoside triphosphates are used in DNA synthesis.

• The synthesis of dihydrofolate is disrupted by methotrexate.
• Those biochemical reactions in the cell that depend on one-carbon metabolism can't be carried out because of the failure to regenerate tetrahydrofolate.

• Chapter 25 trahydrofolate is required for the inhibition of F-dUMP.
• A deficiency of methylenetetrahydrofolate means that F-dUMP cannot be activated.
• The formation of dihydrofolate can be prevented by F-dUMP.

• The increase in the rate of synthesis of pyrimidines, including orotic acid, can be stimulated by entering the cytosol.
• When any of the urea cycle enzymes are deficient, there is an excess of carbamoylphosphate in the mitochondria.
• A condition like this will lead to hyperammonemia.
• Hyperammonemia can be caused by a deficiency in the pyrimidine synthesis in the cytosol.

• glutamine is the main substance for the formation of carbamoyl phosphate in the cytosol.
• The pyrimidines would be affected by a deficiency in the synthesis of carbamoylphosphate.
• The deficiency can be treated with administration of uracil or uridine.

• The transamination of b-aminoisobutyrate to form methylmalonate semialdehyde is a cofactor.
• The conversion of ornithine to g-semialdehyde is similar.
• The oxidation of methylmalonate semialdehyde to methylmalonate can be accomplished with the help of NAD+.
• Coenzyme A is required for the conversion of methylmalonate to methylmalonyl CoA.
• The final reaction, in which methylmalonyl CoA is converted to succinyl CoA, is catalyzed by methylmalonyl CoA mutase.

• The pathway for purine synthesis shows that only glycine is present in the purine ring at the C-4 and C-5 positions.
• glycine is a good choice.
• Serine plays a role in the formation of purines because it is a precursor of glycine and the ultimate donor of C-1 groups.

• The relative amounts of the two unlabeled amino acids in the cell are what determines whether serine is a better choice than glycine.

• 6-thioinosine5'-monophosphate is an analogue of IMP.

• There is a higher level of conversion of 6-MP into 6-TNG due to the increase in substrate availability.
• 6-MP can compete with purine bases for HGPRT, which can lead to a decrease in the synthesis ofAMP and GMP.

• Hydroxyurea is an anti- ribonucleotide reductase.
• The organic free radical in the R2 subunit is destabilized by hydroxyurea.
• Deoxyribonucleoside diphosphates are normally converted to deoxyribonucleoside triphosphates when the activity of the enzyme is reduced.

• There are two compounds that are similar to dihydrofolate and dihydrofolate reductase.
• 10-methylenetetrahydrofolate is used in the process of forming dTMP.
• In the presence of one of the inhibitors, this reaction functions as a sink that reduces the THF level of the cell.
• The two reactions of purine metabolism and one of pyrimidine metabolism are affected by the inhibitor.

• Increased levels of deoxyribose 1-phosphate are available for the formation of deoxythymidine in the reverse reaction.

• It is possible to convert elevated levels of deoxyadenosine to dAMP and then to dATP, which could lead to the inactivation of ribonucleotide reductase, which is sensitive to the concentration of dATP.

• The conversion of ribose 1-phosphate to ribose 5-phosphate, which is catalyzed by phosphoribomutase, is the first step in the creation of PRPP.

• Adding ribosephosphate and anamp moiety to nicotinamide will convert it to NAD+.
• The formation of nicotinamide ribonucleotide or nicotinamide mononucleotide is caused by a phosphoribosyl transferase.
• The final step uses an adenyl donor for the formation of the dinucleotide NAD+.

• This reaction raises the steady-state level of PRPP, which in turn increases the activity of PRPP amidotransferase, the first step in purine synthesis.
• The end products of the purine biosynthetic pathway are resistant to feedback inhibition.

• This increases the rate of synthesis of pyrimidine at the orotate phosphoribosyl transferase reaction.
• A reasonable estimate of de novo pyrimidine nucleotide synthesis can be given by rotation into a nucleotide pool or into a nucleic acid.

• The pathway that resembles urea formation in mammals is a part of Arginine biosynthesis.
• There are two forms of pyrimidine synthesis used in mammals.
• The pyrimidine synthesis step is regarded as the committed step because the two pathways are separated.

• An increase in dCTP levels is indicative of the cell's need for a synthesis drug.
• An increase in dTTP levels indicates that the activity of thymidylate synthase can be decreased and that the inhibition of dCMP deaminase by dTTP reduces the input of dUMP into the pathway.
• ribonucleotide reductase is not subject to allosteric regulation by dCTP.
• It appears that regulation of dCMP deaminase provides a second control point for the generation of deoxynucleotides in the cell.

• 2 ATP + NAD+ orotate + 2 ADP + 2 Pi glutamate + NADH + H+ 3.

• The first two reactions in the first stage of purine biosynthesis are what accumulate.
• The precursor molecule will accumulate if the glutaminerequiring amidotransferase reactions are stopped.
• Since the synthesis of formylglycinamide requires that PRPP be converted to phosphoribosylamine, the only thing that will accumulate is PRPP.

• The regenerated coenzyme does not show up in the equation.

• In the de novo pathway of purine formation, phosphoribosylamine is the intermediate that is activated in the formation of pyrimidine.

• Cell B can't grow in this medium because it can't make purines by either of the pathways.

• C can grow in a HAT medium if it has active thymidine kinase from cell B and hypoxanthine-guanine phosphoribosyl transferase from cell A.

• The patients have high levels of urate because of the breakdown of nucleic acids.

• Allopurinol prevents the formation of stones in the kidneys by blocking the formation of urate.

• The free energy of binding can be calculated using the values given.

• 6 log equals 3.

• IMP is the product of the pathway for de novo purine synthesis.
• With the de novo pathway for preformed purines not working effectively, it would be helpful to stimulate the salvage pathway with a diet that is rich in nucleotides that would then be a source of the purine bases hypoxanthine, adenine, and guanine.

• In hypoxanthine, the N and C atoms are interchanged at positions 7 and 8.

• In the production of glycine ribonucleotide, an acylphosphate is formed by the reaction of a carboxylic acid and an acyl acid.

• There is a dehydration and ring closing reaction.

• CHAPTER 25 (c) is a source ofphosphate.

• It's not possible to regenerate methionine in a deficiency of vitamins B12 and B13.
• The cell's tetrahydrofolate will eventually be converted into this form because the synthesis of methyltetrahydrofolate is irreversible.
• No formyl or methylene will be used for synthesis.

• There is an intimate connection between the two metabolisms.
• The metabolism of fatty acids that have odd numbers of carbons will be affected by the requirement of vitamins B12 and B6 for the production of succinyl-CoA.
• There is a connection between the degradation of valine and isoleucine.

• The excess urate is degraded.
• C. R. Scriver, A. L. Beaudet, and W.S.
• are related.

• oxaloacetate can be converted to succinate by the citric acid cycle.
• The oxaloacetate can be transaminated to yield a key ingredient in pyrimidines.

• Half of the ADP can be converted to ATP at the expense of the other half.

• The interconversion of (2ADP) with (ATP +AMP) is essentially isoenergetic.